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Available online 22 October 2015It is well known that the maximum reduction of tumour burden
in malignancies such as ovarian cancer, colon cancer and renal cell
carcinoma, can improve survival and increase response to systemic
therapy. Androgen-deprivation therapy (ADT) is considered the
standard therapy for patients with metastatic disease at the time of
diagnosis, while deﬁnitive local therapy such as radical prostatec-
tomy (RP) and radical radiation are often reserved for patients with
organ-conﬁned disease. However, the optimal treatment for met-
astatic prostate cancer (mPC) remains inconclusive.
Recently, a growing number of research suggest that the effec-
tive local management of mPC may help suppress systemic disease
progression and improve patients' survival. Antwi et al reviewed
the records of 7858 mPC patients, including 222 with RP, 120 with
brachytherapy (BT) and 7516 with no deﬁnitive local therapy
(NDLT).1 Patients who underwent RP or BT were signiﬁcantly less
likely to die from prostate cancer (PC) compared to NDLT. In a
multivariable survival model, RP was associated with a 73% lower
risk of death from all causes and 72% lower risk of death from PC
compared to NDLT. In another SEER database based study, Culp et al
reported that the 5-year overall survival (OS) was signiﬁcantly
higher in patients undergoing either RP (67.4%) or BT (52.6%)
compared with patients who had no surgery or underwent radia-
tion therapy (22.5%) (p<0.001).2 A Munich Cancer Registry (MCR)
based research showed a similar result. mPC patients in the RP
group had a higher 5-year OS rate than the non-RP group (55% vs.
21%; p<0.01).3 Fossati et al, in their aim to identify optimal candi-
dates for local treatment (LT) among mPC patients, found that for
patients with a predicted cancer-speciﬁc mortality (CSM) risk of
<40%, the local treatment of the primary tumour conferred a higher
CSM-free survival rate than patients with no local treatment.4* Corresponding author: LiQun Zhou (zhoulqmail@sina.com).
http://dx.doi.org/10.1016/j.prnil.2015.10.009
p2287-8882 e2287-903XWhen the predicted CSM risk exceeded 50%, LT did not provide a
survival beneﬁt. In a case control study, Heidenreich et al revealed
that RP patients followed by ADT experienced signiﬁcantly better
clinical progression-free survival and cancer speciﬁc survival than
control group patients (on ADT only).5
There are several potential mechanisms by which treatment of
the primary tumour can decrease disease progression. These
include eliminating the source of future metastatic sites, blocking
the delivery of tumor cells into circulation and improving the
response of metastatic sites to subsequent systemic therapy.
Although the available data are encouraging, RP should not be
performed for patients with metastatic disease except of clinical
trials due to limitations of the data. There are several ongoing clinical
trials, aimed at evaluating the beneﬁt of treating primary tumor in
mPC patients, including a randomised trial at the MD Anderson
Cancer Center (NCT01751438) and the STAMPEDE trial
(NCT00268476) in the UK. With initial experience and data from
these ongoing clinical trials, wemay have the opportunity to advance
the care of a previously under-treated population of patients.Conﬂicts of interest
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